Potent neutralization of staphylococcal enterotoxin b by synergistic action of chimeric antibodies

Infection and Immunity

Volumn 78, Issue 6, 2010, Pages 2801-2811

  Tilahun, Mulualem E ^a,b   Rajagopalan, Govindarajan ^c   Shah Mahoney, Nalini ^a   Lawlor, Rebecca G ^b   Tilahun, Ashenafi Y ^c   Xie, Chen ^a   Natarajan, Kannan ^d   Margulies, David H ^d   Ratner, David I ^a   Osborne, Barbara A ^b   Goldsby, Richard A ^a,b  

^a AMHERST COLLEGE   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; CYTOKINE; HLA DR3 ANTIGEN; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; STAPHYLOCOCCUS ENTEROTOXIN B;

ANIMAL CELL; ANTIBODY AFFINITY; ANTIGEN BINDING; ARTICLE; BIOENGINEERING; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MAMMAL CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTITOXINS; BLOOD; CELLS, CULTURED; CYTOKINES; ENTEROTOXINS; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; SPLEEN; STAPHYLOCOCCUS AUREUS;

EID: 77952718853     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01121-09     Document Type: Article

References (54)

1. Arad, G., D. Hillman, R. Levy, and R. Kaempfer. 2004. Broad-spectrum immunity against superantigens is elicited in mice protected from lethal shock by a superantigen antagonist peptide. Immunol. Lett. 91:141-145.
2. Arad, G., D. Hillman, R. Levy, and R. Kaempfer. 2001. Superantigen antagonist blocks Th1 cytokine gene induction and lethal shock. J. Leukoc. Biol. 69:921-927.
3. Arad, G., R. Levy, D. Hillman, and R. Kaempfer. 2000. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat. Med. 6:414-421.
4. Bergdoll, M. S. 1983. Enterotoxins, p. 559-598. In C. S. F. Easom and C. Adlam (ed.), Staphylococci and staphylococcal infections. Academic Press, Inc., New York, NY.
5. Boles, J. W., M. L. M. Pitt, R. D. LeClaire, P. H. Gibbs, E. Torres, B. Dyas, R. G. Ulrich, and S. Bavari. 2003. Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin. Immunol. 108:51-59.
6. Boye, J., T. Elter, and A. Engert. 2003. An overview of the current clinical use of the anti-CD20 monoclonal antibody Rituximab. Ann. Oncol. 14:520-535.
7. Buonpane, R. A., H. R. O. Churchill, B. Moza, E. J. Sundberg, M. L. Peterson, P. M. Schlievert, and D. M. Kranz. 2007. Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Nat. Med. 13:725-729.
8. Carter, P. J. 2006. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6:343-357.
9. Darenberg, J., N. Ihendyane, J. Sjölin, E. Aufwerber, S. Haidl, P. Follin, J. Andersson, and A. Norrby-Teglund. 2003. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 37:333-340.
10. Darenberg, J., B. Söderquist, B. Henriques Normark, and A. Norrby-Teglund. 2004. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin. Infect. Dis. 38:836-842.
11. DaSilva, L., B. C. Welcher, R. G. Ulrich, M. J. Aman, C. S. David, and S. Bavari. 2002. Humanlike immune response of human leukocyte antigen-DR3 transgenic mice to staphylococcal enterotoxins: a novel model for superantigen vaccines. The J. Infect. Dis. 185:1754-1760.
12. Descotes, J., and A. Gouraud. 2008. Clinical immunotoxicity of therapeutic proteins. Expert Opin. Drug Metab. Toxicol. 4:1537-1549.
13. Fraser, J. D. 1989. High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR. Nature 339:221-223. (Pubitemid 19126393)
14. Fraser, J. D., and T. Proft. 2008. The bacterial superantigen and superantigen-like proteins. Immunol. Rev. 225:226-243.
15. Gill, D. M. 1982. Bacterial toxins: a table of lethal amounts. Microbiol. Mol. Biol. Rev. 46:86-94.
16. Goldsby, R. A. 1989. A practical guide to making hybridomas, p. 367. In B. Swaminathan and G. Prakash (ed.), Nucleic acid and monoclonal antibody probes. Marcel-Dekker, New York, NY.
17. Hamad, A., A. Herman, P. Marrack, and J. Kappler. 1994. Monoclonal antibodies defining functional sites on the toxin superantigen staphylococcal enterotoxin B. J. Exp. Med. 180:615-621.
18. Herman, A., J. W. Kappler, P. Marrack, and A. M. Pullen. 1991. Superantigens: mechanism of T-cell stimulation and role in immune responses. Annu. Rev. Immunol. 9:745-772.
19. Hong-Geller, E., M. Möllhoff, P. R. Shiflett, and G. Gupta. 2004. Design of chimeric receptor mimics with different TCR Vβ isoforms: type-specific inhibition of superantigen pathogenesis. J. Biol. Chem. 279:5676-5684.
20. Idusogie, E. E., L. G. Presta, H. Gazzano-Santoro, K. Totpal, P. Y. Wong, M. Ultsch, Y. G. Meng, and M. G. Mulkerrin. 2000. Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164:4178-4184.
21. Jolles, S., W. A. C. Sewell, and S. A. Misbah. 2005. Clinical uses of intravenous immunoglobulin. Clin. Exp. Immunol. 142:1-11.
22. Kappler, J., B. Kotzin, L. Herron, E. Gelfand, R. Bigler, A. Boylston, S. Carrel, D. Posnett, Y. Choi, and P. Marrack. 1989. Vβ-specific stimulation of human T cells by staphylococcal toxins. Science 244:811-813. (Pubitemid 19163867)
23. Kaul, R., A. McGeer, A. Norrby-Teglund, M. Kotb, B. Schwartz, K. O'Rourke, J. Talbot, and D. E. Low. 1999. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. Clin. Infect. Dis. 28:800-807.
24. Kindt, T. J., R. A. Goldsby, B. A. Osborne, and J. Kuby. 2007. Kuby immunology, 6th ed. W. H. Freeman and Company, New York, NY.
25. Lavoie, P. M., J. Thibodeau, F. Erard, and R. P. Sékaly. 1999. Understanding the mechanism of action of bacterial superantigens from a decade of research. Immunol. Rev. 168:257-269.
26. LeClaire, R. D., R. E. Hunt, and S. Bavari. 2002. Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. Infect. Immun. 70:2278-2281.
27. Lehnert, N. M., D. L. Allen, B. L. Allen, P. Catasti, P. R. Shiflett, M. Chen, B. E. Lehnert, and G. Gupta. 2001. Structure-based design of a bispecific receptor mimic that inhibits T cell responses to a superantigen. Biochemistry 40:4222-4228.
28. Li, H., A. Llera, E. L. Malchiodi, and R. A. Mariuzza. 1999. The structural basis of T-cell activation by superantigens. Annu. Rev. Immunol. 17:435-466.
29. Lowell, G., C. Colleton, D. Frost, R. Kaminski, M. Hughes, J. Hatch, C. Hooper, J. Estep, L. Pitt, M. Topper, R. Hunt, W. Baker, and W. Baze. 1996. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Infect. Immun. 64:4686-4693.
30. Lowell, G., R. Kaminski, S. Grate, R. Hunt, C. Charney, S. Zimmer, and C. Colleton. 1996. Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice. Infect. Immun. 64:1706-1713.
31. Maini, R., E. W. St. Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, J. Smolen, P. Emery, G. Harriman, M. Feldmann, and P. Lipsky. 1999. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932-1939.
32. Marrack, P., M. Blackman, E. Kushnir, and J. Kappler. 1990. The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells. J. Exp. Med. 171:455-464.
33. Marrack, P., and J. Kappler. 1990. The staphylococcal enterotoxins and their relatives. Science 248:705-711.
34. McCormick, J. K., J. M. Yarwood, and P. M. Schlievert. 2001. Toxic shock syndrome and bacterial superantigens: an update. Annu. Rev. Microbiol. 55:77-104.
35. Miethke, T., C. Wahl, K. Heeg, B. Echtenacher, P. Krammer, and H. Wagner. 1992. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J. exp. Med. 175:91-98.
36. Möllhoff, M., H. B. V. Zanden, P. R. Shiflett, and G. Gupta,. 2005. Modeling of receptor mimics that inhibit superantigen pathogenesis. J. Mol. Recog. 18:73-83.
37. Norrby-Teglund, A., H. Basma, J. Andersson, M. Allison, D. E. Low, and M. Kotb. 1998. Varying titers of neutralizing antibodies to streptococcal super-antigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin. Infect. Dis. 26:631-638.
38. Norrby-Teglund, A., R. Kaul, D. Low, A. McGeer, D. Newton, J. Andersson, U. Andersson, and M. Kotb. 1996. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T-cell proliferation and cytokine production. J. Immunol. 156:3057-3064. (Pubitemid 126660657)
39. Pang, L. T. Y., W. W. S. Kum, and A. W. Chow. 2000. Inhibition of staphylococcal enterotoxin B-induced lymphocyte proliferation and tumor necrosis factor alpha secretion by MAb5, an anti-toxic shock syndrome toxin 1 monoclonal antibody. Infect. Immun. 68:3261-3268.
40. Persic, L., A. Roberts, J. Wilton, A. Cattaneo, A. Bradbury, and H. R. Hoogenboom. 1997. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 187:9-18. (Pubitemid 27110429)
41. Petersson, K., G. Forsberg, and B. Walse. 2004. Interplay between super-antigens and immunoreceptors. Scand. J. Immunol. 59:345-355.
42. Proft, T., and J. D. Fraser. 2003. Bacterial superantigens. Clin. Exp. Immunol. 133:299-306.
43. Rajagopalan, G., K. Iijima, M. Singh, H. Kita, R. Patel, and C. S. David. 2006. Intranasal exposure to bacterial superantigens induces airway inflammation in HLA class II transgenic mice. Infect. Immun. 74:1284-1296.
44. Rajagopalan, G., M. M. Sen, and C. S. David. 2004. In vitro and in vivo evaluation of staphylococcal superantigen peptide antagonists. Infect. Immun. 72:6733-6737.
45. Roy, C. J., K. L. Warfield, B. C. Welcher, R. F. Gonzales, T. Larsen, J. Hanson, C. S. David, T. Krakauer, and S. Bavari. 2005. Human leukocyte antigen-DQ8 transgenic mice: a model to examine the toxicity of aerosolized staphylococcal enterotoxin B. Infect. Immun. 73:2452-2460.
46. Rusnak, J. M., M. Kortepeter, R. Ulrich, M. Poli, and E. Boudreau. 2004. Laboratory exposures to staphylococcal enterotoxin B. Emerg. Infect. Dis. 10:1544-1549.
47. Schlievert, P. M. 1993. Role of superantigens in human disease. J. Infect. Dis. 167:997-1002.
48. Schrage, B., G. Duan, L. P. Yang, J. D. Fraser, and T. Proft. 2006. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. Clin. Infect. Dis. 43:743-746.
49. Sriskandan, S., M. Ferguson, V. Elliot, L. Faulkner, and J. Cohen. 2006. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J. Antimicrob. Chemother. 58:117-124.
50. Taneja, V., and C. S. David. 1999. HLA class II transgenic mice as models of human diseases. Immunol. Rev. 169:67-79.
51. Taneja, V., and C. S. David. 2001. Lessons from animal models for human autoimmune diseases. Nat. Immunol. 2:781-784.
52. Ulrich, R. G., M. A. Olson, and S. Bavari. 1998. Development of engineered vaccines effective against structurally related bacterial superantigens. Vaccine 16:1857-1864.
53. Visvanathan, K., A. Charles, J. Bannan, P. Pugach, K. Kashfi, and J. B. Zabriskie. 2001. Inhibition of bacterial superantigens by peptides and antibodies. Infect. Immun. 69:875-884.
54. Wang, Z., M. Raifu, M. Howard, L. Smith, D. Hansen, R. Goldsby, and D. Ratner. 2000. Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3 to 5 exonuclease activity. J. Immunol. Methods 233:167-177. (Pubitemid 30058245)